14/11/2011
I am happy to inform you that after a period in which the preparation (Sinemet) was marketed temporarily according to regulation 29(a)(3), the registration of the preparation Sinemet CR, which is designed to treat the symptoms of Parkinson's disease, has been updated, and it will now be marketed again in Israeli packaging.

The preparation was recently imported in accordance with regulation 29(a)(3) after and due to a change made in the source of supply of one of the two active ingredients of the preparation. Today, after the change in the aforementioned source of supply has been approved by the Ministry of Health and the preparation's registration has been updated, the preparation will be imported as a registered preparation, and there will no longer be a need for approval according to Rule 29(a)(3).
It should be noted that the source of supply of the active ingredient of the registered preparation that will be marketed from now on is the same as that of the preparation imported until now according to Rule 29(a)(3). and that there has been no change in the composition or quality of the preparation.

The preparation will soon be available in all pharmacies and health insurance funds, subject to a doctor's prescription.
The name of the preparation remains unchanged - Sinemet CR, and will be marketed in a package containing 30 tablets.
For more information, you can contact the MSD company at 09-9533333

Best regards,
Yoav Shechter
Foreign relations manager